FDA Orange Book · active-ingredient family
Celecoxib; tramadol hydrochloride
Celecoxib; tramadol hydrochloride is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:SEGLENTIS · NDA 213426
1
Brand (NDA)
0
Generics (ANDA)
7
Listed patents
0
Exclusivity periods
Brand (NDA) products · tablet
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| SEGLENTISRLD | KOWA PHARMS | NDA 213426 | — | Oct 15, 2021 |
Listed patents (7)
| Patent | Expires | In | Type |
|---|---|---|---|
| 10238668 | Apr 19, 2030 | in 3 yr 11 mo | SubstanceProductU-3244 |
| 10548909 | Apr 19, 2030 | in 3 yr 11 mo | U-3244 |
| 11478488 | Apr 19, 2030 | in 3 yr 11 mo | U-3244 |
| 9012440 | Apr 19, 2030 | in 3 yr 11 mo | SubstanceProduct |
| 10245276 | Apr 19, 2030 | in 3 yr 11 mo | SubstanceProduct |
| 8598152 | Apr 19, 2030 | in 3 yr 11 mo | SubstanceProduct |
| 8846744 | Jun 03, 2031 | in 5 yr | Product |
Celecoxib; tramadol hydrochloride — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
